228 related articles for article (PubMed ID: 20101221)
1. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Santo L; Vallet S; Hideshima T; Cirstea D; Ikeda H; Pozzi S; Patel K; Okawa Y; Gorgun G; Perrone G; Calabrese E; Yule M; Squires M; Ladetto M; Boccadoro M; Richardson PG; Munshi NC; Anderson KC; Raje N
Oncogene; 2010 Apr; 29(16):2325-36. PubMed ID: 20101221
[TBL] [Abstract][Full Text] [Related]
2. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2019 Jun; 513(3):589-593. PubMed ID: 30979499
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy.
Wei X; Nian J; Zheng J; He Y; Zeng M
Cancer Chemother Pharmacol; 2020 May; 85(5):949-957. PubMed ID: 32279103
[TBL] [Abstract][Full Text] [Related]
5. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Squires MS; Cooke L; Lock V; Qi W; Lewis EJ; Thompson NT; Lyons JF; Mahadevan D
Mol Cancer Ther; 2010 Apr; 9(4):920-8. PubMed ID: 20354122
[TBL] [Abstract][Full Text] [Related]
6. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.
Song EY; Palladinetti P; Klamer G; Ko KH; Lindeman R; O'Brien TA; Dolnikov A
Exp Hematol; 2010 Oct; 38(10):908-921.e1. PubMed ID: 20540984
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells.
Yeste-Velasco M; Folch J; Trullàs R; Abad MA; Enguita M; Pallàs M; Camins A
Neuropharmacology; 2007 Aug; 53(2):295-307. PubMed ID: 17612578
[TBL] [Abstract][Full Text] [Related]
10. 2,3,7,8-Tetrachlorodibenzo-p-dioxin stimulates proliferation of HAPI microglia by affecting the Akt/GSK-3β/cyclin D1 signaling pathway.
Xu G; Li Y; Yoshimoto K; Wu Q; Chen G; Iwata T; Mizusawa N; Wan C; Nie X
Toxicol Lett; 2014 Jan; 224(3):362-70. PubMed ID: 24231000
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells.
Yoshino Y; Ishioka C
Sci Rep; 2015 Aug; 5():13249. PubMed ID: 26292722
[TBL] [Abstract][Full Text] [Related]
12. The role of glycogen synthase kinase-3β in glioma cell apoptosis induced by remifentanil.
Xu J; Xu P; Li Z; Xiao L; Yang Z
Cell Mol Biol Lett; 2013 Dec; 18(4):494-506. PubMed ID: 23990403
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3.
Mishra R; Barthwal MK; Sondarva G; Rana B; Wong L; Chatterjee M; Woodgett JR; Rana A
J Biol Chem; 2007 Oct; 282(42):30393-405. PubMed ID: 17711861
[TBL] [Abstract][Full Text] [Related]
14. GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line.
Dickey A; Schleicher S; Leahy K; Hu R; Hallahan D; Thotala DK
J Neurooncol; 2011 Aug; 104(1):145-53. PubMed ID: 21161565
[TBL] [Abstract][Full Text] [Related]
15. Saturated free fatty acid sodium palmitate-induced lipoapoptosis by targeting glycogen synthase kinase-3β activation in human liver cells.
Cao J; Feng XX; Yao L; Ning B; Yang ZX; Fang DL; Shen W
Dig Dis Sci; 2014 Feb; 59(2):346-57. PubMed ID: 24132507
[TBL] [Abstract][Full Text] [Related]
16. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer.
Kang MA; Kim W; Jo HR; Shin YJ; Kim MH; Jeong JH
Int J Oncol; 2018 Aug; 53(2):703-712. PubMed ID: 29901072
[TBL] [Abstract][Full Text] [Related]
17. Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death.
Piazza F; Manni S; Tubi LQ; Montini B; Pavan L; Colpo A; Gnoato M; Cabrelle A; Adami F; Zambello R; Trentin L; Gurrieri C; Semenzato G
BMC Cancer; 2010 Oct; 10():526. PubMed ID: 20920357
[TBL] [Abstract][Full Text] [Related]
18. Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3β-Cyclin D1 pathway.
Ong CS; Zhou J; Ong CN; Shen HM
Cancer Lett; 2010 Dec; 298(2):167-75. PubMed ID: 20655656
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Ban JO; Oh JH; Son SM; Won D; Song HS; Han SB; Moon DC; Kang KW; Song MJ; Hong JT
Cancer Biol Ther; 2011 Aug; 12(4):288-96. PubMed ID: 21613824
[TBL] [Abstract][Full Text] [Related]
20. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor.
Takada Y; Fang X; Jamaluddin MS; Boyd DD; Aggarwal BB
J Biol Chem; 2004 Sep; 279(38):39541-54. PubMed ID: 15252041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
